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DStudy Limitations
The limitations to this study include its retrospective na-
ture. This cohort is also representative of our single-
institution, referral-based practice, and thus our findings
may not be generalizable. The experience reflects a practice
that evolved over 5 decades, although most patients under-
went operations in the recent era of MV repair. Finally,
although our study examined a large number of patients
with MFS who underwent MV surgery, the analysis is un-
derpowered to detect survival differences between the
subgroups.
CONCLUSIONS
To better understand survival and reintervention rates, we
case-matched patients with MFS who underwent MV repair
to patients with myxomatous MV disease who underwent
MV repair; we found no difference in survival or freedom
from reoperation. Durability and long-term survival suggest
that MV repair in patients with MFS may be preferable to
replacement, even in patients who undergo concomitant
aortic valve replacement.
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Dr Duke Cameron (Baltimore, Md). I have no disclosures. Dr
Kunkala, our thanks to you and the Mayo Clinic group for this
article, which clearly shows that MV repair has the same low oper-
ative risk and good long-term durability as in the patient without
MFS with conventional myxomatous MV disease.
My only criticism is that it probably gives an unfairly pessi-
mistic view of the long-term results of MV replacement. Most of
your MV replacement cases were still performed in the first half
of the series at a time when your patients really didn’t have the1024 The Journal of Thoracic and Cardiovascular Surbenefits of modern myocardial protection and postoperative man-
agement and our understanding of how the MV works. In 40% of
your replacements, the MV was completely excised, which is
something we would rarely do today. I wonder, if you looked at
your MV replacements that had been performed in the second
half of the series, in a modern era, are the results really as bad as
they are with the series overall?
Second, you said in the presentation that most patients with
MFS coming from MV surgery are already receiving anticoagula-
tion. I think you probably just meant to say ‘‘some.’’ Because
certainly in the era in which aortic valve-sparing surgery is
becoming so commonplace, the whole idea here is to try to keep
them off anticoagulants altogether.
My third comment regards the technique of mitral repair.
There is no question that the spectrum of MV disease in MFS is
broad, from the simplest P2 prolapse that you see in myxomatous
disease to some of the worst cases of Barlow’s that you could
imagine.
Our experience with these lesions is that the more complex the
mitral pathology, the simpler our repairs have become. You can
spend all day transferring cords and resecting leaflets, but some
of these extreme valves are best served by a ring, plus or minus
the Alfieri stitch, to prevent systolic anterior motion. This has
worked well. Can you comment on that strategy?
Dr Helder. Regarding the survival of the patients with MV
replacement, you are correct that most of these patients had
replacement in an earlier era, and this may have influenced late
outcome. But it is important to recognize that valvuloplasty tech-
niques have improved with time, and the outcome of valve repair
performed in the earlier era may not be equivalent to results today.
Regarding your comment on anticoagulation, you are correct that
in current practice many or most patients undergo valve-sparing
operations and would not require anticoagulation for an aortic
prosthesis. We agree with your strategy for using less complex
techniques for MV repair in patients with MFS and for the larger
population of patients presenting for MV repair.
Dr Pirooz Eghtesady (St Louis, Mo). I noticed on one of your
slides the overall intervention rate for the MV had increased sub-
stantially with, obviously, a larger percentage being MV repairs in
the most recent era. Is that because indications have changed?
You’re being more aggressive? How would you characterize that?
Dr Helder. I think the reason for more MV repairs is that sur-
geons are becoming more comfortable with various repair tech-
niques to address a wider variety of mitral pathologies.
Dr Scott LeMaire (Houston, Tex). Did you look at specific
valve-related complications at all, such as thromboembolism or
bleeding complications, in the 2 cohorts?
Dr Helder. Of the 21 patients who had MV replacement, 3
developed transient ischemic attacks. So in that small number, I
guess we could say that the replacement cases had a little bit
more of an embolic phenomenon than the repair cases. Otherwise,
we did not see a difference in bleeding or other embolic events in
either group because the events were fairly low to begin with.
Dr LeMaire. I may have missed it, but was there any difference
in the need for subsequent procedures on the MV in the 2 groups?
Dr Helder. There was not. There was no statistically significant
difference between MV reoperation rates between the repair and
replacement groups.gery c September 2014
